Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation

Liver Transplantation

Volumn 19, Issue 6, 2013, Pages 594-601

  Teperman, Lewis W ^a   Poordad, Fred ^b   Bzowej, Natalie ^c   Martin, Paul ^d   Pungpapong, Surakit ^e   Schiano, Thomas ^f   Flaherty, John ^g   Dinh, Phillip ^g   Rossi, Stephen ^g   Subramanian, G Mani ^g   Spivey, James ^h  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f MOUNT SINAI HOSPITAL   (United States)

^g GILEAD SCIENCES   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B ANTIBODY; ADENINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSURIA; HEPATITIS B; HUMAN; HYPERGLYCEMIA; INFECTION PREVENTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ULCERATIVE COLITIS; VIRUS INHIBITION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HEPATITIS B, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; UNITED STATES;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 84878317081     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23628     Document Type: Article

References (30)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE,. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626.
2. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-815.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H,. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
4. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER,. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968-974.
5. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850.
6. Dan YY, Wai CT, Yeoh KG, Lim SG,. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746.
7. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182-187.
8. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS,. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381.
9. Angus PW, Patterson SJ,. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl 2008; 14 (suppl 2): S15-S22.
10. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
11. Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535.
12. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
13. Degertekin B, Lok AS,. What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation? Nat Clin Pract Gastroenterol Hepatol 2009; 6: 68-69.
14. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
15. Mutimer D,. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006; 23: 1031-1041.
16. Fabarius A, Leitner A, Hochhaus A, Müller MC, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group. Impact of additional cytogenetic alterations at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV [abstract]. Blood 2011; 118: 6760-6768.
17. Truvada (emtricitabine/tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences; 2011.
18. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E,. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 4771-4779.
19. Viread (tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences; 2011.
20. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
21. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed February 2013.
22. Engell CA, Pham VP, Holzman RS, Aberg JA,. Virologic outcome of using tenofovir/emtricitabine to treat hepatitis B in HIV-coinfected patients. ISRN Gastroenterol 2011; 2011: 405390.
23. Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, et al. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res 2011; 92: 90-95.
24. Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, et al. High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin Gastroenterol 2011; 45: 900-905.
25. Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011; 91: 916-920.
26. Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, et al. Substitution of tenofovir/emtricitabine for hepatitis B immune globulin prevents recurrence of hepatitis B after liver transplantation. Liver Int 2012; 32: 1138-1145.
27. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
28. Weber NK, Forman LM, Trotter JF,. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-509.
29. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
30. Aberg F, Koivusalo AM, Höckerstedt K, Isoniemi H,. Renal dysfunction in liver transplant patients: comparing patients transplanted for liver tumor or acute or chronic disease. Transpl Int 2007; 20: 591-599.